Figure 1 Flow diagram of systematic review

Slides:

Advertisements

Similar presentations

Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies by Lawrence de Koning,

Advertisements

An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study by Peter Barlis, Evelyn.

Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay:

Why are drug-eluting stents safer than bare-metal stents? Giuseppe Biondi Zoccai, MD Sapienza University of Rome, Rome, Italy METCARDIO,

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty:

Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis by Tuula A. Paajanen, Niku K.J. Oksala,

Randomized, non-inferiority trial of three limus agent- eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.

Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.

From: Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions: 2-Year Follow-Up From the Zilver PTX Randomized and Single-Arm.

Jose M. de la Torre Hernández … in behalf of the 3D investigators

Harvard Clinical Research Institute, Boston, US

Figure 2. CONSORT flow diagram.

Multivessel PCI: Pearls of Wisdom (?) for Success

Figure 1 Flow diagram displaying the proportions of patients with troponin measurements available from all eligible patients and the resulting study population.

Current Problems in Cardiology

Figure 1 Ischaemic endpoints

Figure 1 A flow chart describing the systematic process followed for article selection. From: A systematic review of cost-effectiveness of percutaneous.

insights from a meta-analysis of

Figure 1 Patient flow chart.

12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Meta-Analysis of Three Randomized Trials and Nine Observational Studies Comparing Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Unprotected.

Retrospective Study of First-Generation Drug-Eluting Stents, Second-Generation Drug- Eluting Stents and Non-Drug Eluting Stent Methods in the Treatment.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 2 The incidence of new onset AF, strokes, heart failure, and mortality according to the BMI (/ person-years). (Left: BMI

Median target vessel revascularization rates per 1000 patient-years of follow-up with bare metal stents (BMS) and first- and second-generation drug-eluting.

Figure 1 Flow chart of study selection.

Figure 1 Principal degradation characteristics of CE-marked bioresorbable scaffolds. For each device data are shown, where available, for radial support.

Figure 1 Flow chart of search and selection strategy for studies in a systematic review of endometrial thickness during IUI with ovarian stimulation. *

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1 Study flow chart

Figure 2 Comparison of pregnancy outcomes between true NC-FET and modified NC-FET. Odds ratio (OR) adjusted for clinical pregnancy (OR 0.90, 95% CI 0.73–1.12)

Figure 1 PRISMA flow diagram illustrating the process of selection of studies for inclusion in the systematic review. From: How effective are weight-loss.

Second Generation DES Associated with Less Late and Very Late Stent Thrombosis Compared to First Generation DES Donald E. Cutlip, MD Beth Israel Deaconess.

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Stenting of Coronary Arteries in Non Stress/Benestent Disease

Circ Cardiovasc Interv

Comparison of prevalence of uncovered struts between ZES and EES groups. Comparison of prevalence of uncovered struts between ZES and EES groups. Scatter plot.

Catheter-Based Treatment of Coronary Artery Disease

Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis Suetonia C. Palmer, MBChB,

The Role of Systematic Reviews and Meta-analysis in Dermatology

Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis S Hajibandeh, S Hajibandeh,

Nat. Rev. Cardiol. doi: /nrcardio

Background There is ongoing debate to identify the most effective drug-eluting stent between the two currently most used devices (ie, sirolimus- [SES]

Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery Konstantinos.

Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year.

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

Systematic review or meta-analysis

Paclitaxel-coated balloon reduces target lesion revascularization compared with standard balloon angioplasty Nicholas Candy, MBBS, Eugene Ng, MBBS, Ramesh.

Aaron M. Drucker, Patrick Fleming, An-Wen Chan

A meta-analysis of anticoagulation for calf deep venous thrombosis

Drug-eluting stents for in-stent restenosis

European Society of Cardiology Scientific Congress, September 2006

Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.

Tornado diagram of one-way deterministic sensitivity analysis.

John A. Bittl et al. JACC 2016;68:

Figure 1 Mechanism of mortality benefit associated with radial access

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Relationships between magnitude of antithrombotic benefit vs

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Yin-Shu Chang, MD, Jia-Xiang Wang, MD, PhD, Da-Wei Chang, PhD

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and.

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Presentation transcript:

Figure 1 Flow diagram of systematic review Figure 1 Flow diagram of systematic review. The study flow diagram was depicted following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement. RCT, randomized controlled trial; DES, drug-eluting stent. From: Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J. 2014;35(17):1147-1158. doi:10.1093/eurheartj/eht570 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com

Figure 2 Network plot of included trials Figure 2 Network plot of included trials. Each stent is represented by a node. The size of the node is proportional to the sample size randomized to each stent, while the thickness of the line connecting the nodes is to the total randomized sample size in each pairwise treatment comparison. BMS, bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, endeavor zotarolimus-eluting stents; CoCr-EES, cobalt–chromium everolimus-eluting stents; PtCr-EES, platinum–chromium everolimus-eluting stents; ZES-R, resolute zotarolimus-eluting stents; BP-BES, biodegradable-polymer-biolimus-eluting stents. From: Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J. 2014;35(17):1147-1158. doi:10.1093/eurheartj/eht570 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com

Figure 3 Risk of bias assessment Figure 3 Risk of bias assessment. Risk of bias of each included trial was assessed with the Cochrane Collaboration's tool. This ‘risk of bias graph’ illustrates the proportion of studies with each of the judgements for each entry in the tool. Green represents ‘yes (low risk of bias)’; yellow, ‘unclear’; red, ‘no (high risk of bias)’. From: Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J. 2014;35(17):1147-1158. doi:10.1093/eurheartj/eht570 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com

Figure 4 Definite or probable stent thrombosis within 1 year Figure 4 Definite or probable stent thrombosis within 1 year. The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for definite or probable stent thrombosis within 1 year estimated with multiple-treatment meta-analysis. BMS, bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, endeavor zotarolimus-eluting stents; CoCr-EES, cobalt–chromium everolimus-eluting stents; PtCr-EES, platinum-chromium everolimus-eluting stents; ZES-R, resolute zotarolimus-eluting stents; BP-BES, biodegradable-polymer-biolimus-eluting stents. From: Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J. 2014;35(17):1147-1158. doi:10.1093/eurheartj/eht570 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com

Figure 5 Definite or probable stent thrombosis with reference to bare metal stent. The squares and horizontal lines indicate odds ratios and their 95% credible intervals for definite or probable stent thrombosis estimated with multiple-treatment meta-analysis. All comparisons are presented with reference to bare metal stent. ST, stent thrombosis; BMS, bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, endeavor zotarolimus-eluting stents; CoCr-EES, cobalt–chromium everolimus-eluting stents; PtCr-EES, platinum–chromium everolimus-eluting stents; ZES-R, resolute zotarolimus-eluting stents; BP-BES, biodegradable-polymer-biolimus-eluting stents. From: Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J. 2014;35(17):1147-1158. doi:10.1093/eurheartj/eht570 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com

Figure 6 Definite stent thrombosis within 1 year Figure 6 Definite stent thrombosis within 1 year. The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for definite stent thrombosis within 1 year estimated with multiple-treatment meta-analysis. BMS, bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, endeavor zotarolimus-eluting stents; CoCr-EES, cobalt–chromium everolimus-eluting stents; PtCr-EES, platinum–chromium everolimus-eluting stents; ZES-R, resolute zotarolimus-eluting stents; BP-BES, biodegradable-polymer-biolimus-eluting stents. From: Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J. 2014;35(17):1147-1158. doi:10.1093/eurheartj/eht570 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com

Figure 7 Consistency between direct and indirect estimates of stent thrombosis comparing (A) BP-BES vs. BMS and (B) CoCr-EES vs. BP-BES. BMS, bare metal stents; CoCr-EES, cobalt–chromium everolimus-eluting stents; BP-BES, biodegradable-polymer-biolimus-eluting stents; OR, odds ratio; SE, standard error. From: Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J. 2014;35(17):1147-1158. doi:10.1093/eurheartj/eht570 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com

Figure 9 Myocardial infarction within 1 year Figure 9 Myocardial infarction within 1 year. The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for myocardial infarction within 1 year estimated with multiple-treatment meta-analysis. BMS, bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, endeavor zotarolimus-eluting stents; CoCr-EES, cobalt–chromium everolimus-eluting stents; PtCr-EES, platinum–chromium everolimus-eluting stents; ZES-R, resolute zotarolimus-eluting stents; BP-BES, biodegradable-polymer-biolimus-eluting stents. From: Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J. 2014;35(17):1147-1158. doi:10.1093/eurheartj/eht570 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com

Figure 8 Target lesion revascularization within 1 year Figure 8 Target lesion revascularization within 1 year. The squares and horizontal lines indicate pairwise odds ratios and their 95% credible intervals for target lesion revascularization within 1 year estimated with multiple-treatment meta-analysis. BMS, bare metal stents; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; ZES-E, endeavor zotarolimus-eluting stents; CoCr-EES, cobalt–chromium everolimus-eluting stents; PtCr-EES, platinum–chromium everolimus-eluting stents; ZES-R, resolute zotarolimus-eluting stents; BP-BES, biodegradable-polymer-biolimus-eluting stents. From: Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J. 2014;35(17):1147-1158. doi:10.1093/eurheartj/eht570 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com